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Abstract Background: Imatinib mesylate blocks the
tyrosine kinase activity of KIT (CD117) and is an
effective treatment for gastrointestinal stromal tumors.
In multiple myeloma, KIT expression has been detected
by flow cytometry in about 33% of specimens, but no
previous immunohistochemical assessment has yet been
made of the expression pattern of KIT. Materials and
methods: We performed immunohistochemical analyses
of 100 patients, including 72 with multiple myeloma
(MM), 8 with lymphoplasmacytic lymphoma (LPL), 10
with monoclonal gammopathy of undetermined signifi-
cance (MGUS) and 10 with reactive plasmocytosis. One
KIT-positive MM was sequenced using polymerase chain
reaction analysis. Results: In MM, only 2 cases (2.8%)
were KIT positive. The great majority of the cases (97,
2%) did not express the KIT receptor tyrosine kinase. No
mutation of the c-kit gene was detected. Conclusions:
KIT expression is a rare event in MM and not detectable
in MGUS and LPL. Therefore, treatment with imatinib is
unlikely to be effective in these patients.
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Introduction
Imatinib mesylate (Glivec) is a specific inhibitor of
tyrosine kinases, such as Abl, KIT (CD117) and platelet-
derived growth factor receptor (PDGF-R). Several studies
have shown the effectiveness of imatinib mesylate as a
molecular target treatment in chronic myelogenous leu-
kemia [9] via blockade of bcr-abl activity, in gastrointes-
tinal stromal tumors (GIST) [4, 15] via KIT inhibition and
in dermatofibrosarcoma protuberans [14] and hypere-
osinophilic syndrome [3] via interference with PDGF-R
activation. This has raised hopes that other malignancies
resulting from oncogenic activation of these kinases may
benefit from molecular target therapy.
Multiple myeloma (MM) is a malignant plasma cell
neoplasia, characterized by osteolytic lesions, marrow
plasmocytosis and monoclonal gammopathy [7]. Current-
ly, the therapy for MM includes conventional low-dose
chemotherapy or high-dose chemotherapy with autolo-
gous or allogeneic stem cell transplantation. Although the
tumor burden can be reduced, a complete and sustained
remission of disease is rare, and most of the patients
suffer from relapsing disease [16]. Therefore, novel
therapies are urgently needed. Because flow cytometry
has revealed KIT expression in 33% of MM (range 26–
43%) [1, 5, 10, 11, 12], aberrant KIT expression in MM
could provide the rationale for treatment with imatinib
mesylate. However, no immunohistochemical analysis
assessing the in situ expression of KIT in MM has been
performed prior to the study reported herein.
The aim of our study was to investigate KIT expression
by immunohistochemical analysis in a large cohort of
bone-marrow biopsies of patients with MM, monoclonal
gammopathy of undetermined difference (MGUS), lym-
phoplasmacytic lymphoma (LPL) and reactive plasmacy-
tosis (RP) to provide the histopathological basis for a pu-
tative molecular-targeted therapy with imatinib mesylate.
Materials and methods
Patients
We retrospectively reviewed bone marrow biopsies of 100 patients,
90 with monoclonal gammopathies (72 MM, 8 LPL and 10 MGUS)
and 10 with RP, retrieved from the archives of the Institute of
Pathology, University of Basel.
The diagnoses of MM, LPL, MGUS and RP were established by
histomorphology and immunohistochemistry. All specimens were
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reviewed and reclassified according to the World Health Organi-
zation classification criteria [6].
Immunohistochemistry
Serial sections 4-mm thick of 99 SUSA- and 1 formalin-fixed
paraffin-embedded bone-marrow biopsies were used for immuno-
histochemical studies. The primary antibodies used in this study
and types of antigen retrieval performed are summarized in Table 1.
Heat-induced antigen retrieval was performed in a microwave
in ethylene diamine tetraacetic acid buffer (pH 8.0). An automated
modified streptavidin-biotin system (Ventana Medical Systems,
Tucson, AZ) was used for immunohistochemical staining. Mast
cells served as internal positive control and a mutation-confirmed
GIST as external positive control for CD117. Moreover, to obtain
definite specificity control for CD117, the reaction was blocked by
pre-incubation of the primary antibody with the specific antigen
(10 nmol/ml diluted antibody, Novocastra). Positivity was defined
as more than 10% KIT-positive plasma cells, considering only a
membranous staining pattern.
Polymerase chain reaction sequence analysis
One MM with moderate CD117 staining was selected for KIT
mutation analysis [the MM with weak CD117 staining could not be
analyzed by polymerase chain reaction (PCR) due to SUSA fixation
of the bone marrow biopsy]. Deparaffinizing the formalin-fixed
tissues and DNA extraction was performed using a commercial
DNA extraction kit (Qia Amp DNA mini-kit, Cat. #51304, Qiagen
GmbH, Hilden, Germany). Exons 2, 8, 9, 11, 13 and 17 were
amplified using a semi-nested PCR approach and were sequenced
using the Big Dye Terminators Cycle Sequencing Ready Reaction
Kit (Applied Biosystems, Foster City, CA). The primers were
designed based on a previously published sequence of the human c-
kit gene [2]. Sequence products were analyzed on an ABI Prism 310
Genetic Analyzer (Applied Biosystems; Foster City, CA, USA).
Results
Patients
The median age of the various patient populations was:
MM (41 males and 31 females) 66 years (range: 31–
89 years), LPL (8 males) 70 years (range: 52–81 years),
MGUS (3 males and 7 females) 64 years (range: 36–
80 years) and RP (5 males and 5 females) 73 years (range:
52–81 years) (Table 2).
Immunohistochemistry
The monotypic immunoglobulin detected in the 72 MM
patients was IgG in 53% (21% kappa and 32% lambda)
and IgA in 28% (15% kappa and 13% lambda). Mono-
typic light chains only were observed in 19% (equal
distribution of kappa and lambda). In the eight LPL
patients, IgM-kappa was found in 75% and IgM-lambda
in 25%. In the ten MGUS patients, the M-component was
IgG in 60% (kappa in 50% and lambda in 10%), IgA-
lambda in 20%, IgM-kappa in 10% and only light chain
(lambda) in 10%, respectively. Of the 72 MM cases, two
(2.8%) were immunohistochemically KIT positive. One
case (IgG-kappa) showed a moderate membranous ex-
pression in nearly 100% of the plasma cells (Fig. 1A, B,
C), and the other case (IgG-lambda) showed a weak
expression in 50% of the plasma cells (Fig. 2). Of MM,
97% (70/72) were KIT negative, and 100% of LPL,
MGUS and RP were KIT negative.
Table 1 Primary antibodies
and antigen retrieval tech-
niques. MW microwave-based
antigen retrieval with ethylene
diamine tetraacetic acid buffer,
pH 8.0
Antibody Clonality Antigen retrieval Dilution Source Code number
CD117 Polyclonal MW; 100C, 150 1:40 Dako A4502
CD138 Monoclonal MW; 100C, 150 1:15 Dako M7228
IgG Polyclonal None 1:5000 Dako A0423
IgA Polyclonal None 1:10,000 Dako A0262
IgM Polyclonal None 1:5000 Dako A0425
Light chain l Polyclonal None 1:10,000 Dako A0193
Light chain k Polyclonal None 1:10,000 Dako A0191





Multiple myeloma LPL MGUS Reactive plasmocytosis
General data
Number of patients 72 8 10 10
Median age,
years (range)
66 (31–89) 70 (52–81) 64 (36–80) 73 (52–81)
Gender male 41 8 3 5
M-component
IgG, kappa 21% 50%
IgG, lambda 32% 10%
IgA, kappa 15% 0%
IgA, lambda 13% 20%
IgM, kappa 0% 75% 10%
IgM, lambda 0% 25% 0%
Lambda, only 9.5% 10%
Kappa, only 9.5% 0%
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KIT positivity in mast cells serving as internal control
was detected in all cases. The definitive specificity
control of the two positive MM cases was obtained by
pre-incubation of the primary antibody.
PCR
DNA was extracted from the MM case with moderate
KIT expression and amplified and sequenced as de-
scribed. No mutation of the exon 2, 8, 9, 11, 13 and 17 of
the c-kit gene was detected.
Discussion
In the present study, we have shown that KIT is rarely
expressed in MM. Only 2 of 72 cases (2.8%) demonstra-
ted immunohistochemically detectable expression, and all
cases of MGUS, RP and LPL were KIT negative.
To our knowledge, this is the first study to systemat-
ically analyze KIT expression in plasma cells on paraffin
sections. Yang et al. assessed the immunophenotype of
cutaneous and extracutaneous mast cell disease on
paraffin sections and included in their study, four cases
of MM without finding KIT expression [17]. Natkunam et
Fig. 1 Bone marrow with diffuse infiltration of atypical plasma
cells in multiple myeloma (Giemsa, 63) (a). Immunostaining for
CD138 (40), showing a strong positivity of malignant plasma cells
(b). Immunostaining for CD117 (40) with moderate positivity in
malignant plasma cells (c)
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al. analyzed the utility of paraffin section immunohisto-
chemistry for KIT in the differential diagnosis of systemic
mast cell disease involving the bone marrow and found no
expression of KIT in various B-cell lymphomas or plasma
cell tumors [8]. The slight discrepancy in KIT detection
between immunohistochemistry and flow cytometry is not
unusual and may be related to fixation and processing or
to the specificity of the anti-CD117 antibodies employed.
Based on our large series of 72 cases and these few
reports from the literature, we conclude that MM is not a
candidate disease for treatment with imatinib mesylate, as
the majority of cases do not express the KIT target. This
conclusion is clearly corroborated by the fact that in the
B2225 study, an international multi-center trial assessing
the efficacy of imatinib mesylate in advanced/metastatic
malignancies, all six patients with MM (some expressing
KIT in >50% of plasma cells) showed disease progression
while under treatment with imatinib (personal communi-
cation with Novartis).
Thus, for the few cases of MM that show KIT
expression, demonstration of the imatinib target is not, in
itself, sufficient to achieve the expected clinical effects.
Obviously, the tyrosine kinase of the involved receptor
should be functionally active, such as in most cases of
GIST [13]. In general, activating oncogenic mutations of
target genes is a prerequisite for a clinical response to
imatinib therapy [3, 4, 9, 14, 15].
In agreement with the clinical data from the B2225
study (myeloma patients with disease progression while
under treatment), PCR analysis of our MM case with
moderate KIT expression revealed a wild-type gene
configuration, i.e., no mutations in exons 2, 8, 9, 11, 13
and 17. Another possible pathway of successful treatment
of MM patients with imatinib could be targeting PDGFR
signaling. We, therefore, tested several anti-PDGFR
antibodies, but did not obtain reliable and reproducible
results. Continuative mutational analysis was not possi-
ble, due to RNA/DNA degradation in SUSA-fixed tissue.
However, based on the clinical findings from the B2225
study mentioned above, a pathogenetic and therapeutic
role of PDGFR in MM is unlikely.
In summary, most cases of MM are immunohisto-
chemically KIT negative. The very few positive cases
probably do not show activating KIT mutations and,
therefore, will not respond to imatinib treatment.
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